• BSD Medical (Salt Lake City) said that the FDA is continuing its review of the company's Humanitarian Device Exemption (HDE) marketing submission for the Company's BSD-2000 Hyperthermia System. The BSD-2000 is designed for use in conjunction with radiation therapy for the treatment of cervical carcinoma patients who are ineligible for chemotherapy.

• Concentric Medical (Mountain View, California) reported the launch of an expanded family of DAC neurovascular catheters. The DAC catheters are used to provide distal access and support in tortuous anatomy commonly encountered in stroke and other neurovascular procedures. The original DAC catheter was launched as a distal access, support and delivery device for use in Merci Retriever procedures. The original product quickly gained favor in both Merci procedures and general neurovascular procedures.

• MedWaves (San Diego) reported ongoing investigational studies to determine the effectiveness of its microwave ablation system for treating soft tissue lesions, such as tumors, in liver and lung. The studies are using MedWaves' AveCure microwave coagulation-ablation system. The AveCure system, which includes a microwave generator and sterile single-patient-use probes, enables the surgeons and interventional radiologists to safely treat soft tissue problems, such as tumors in the liver and lung, using thermal coagulation-ablation. AveCure uses temperature and power feedback from the antenna and nearby tissue to intelligently control microwave power to the ablation zone. The changes in temperature and power absorption are indicative of thermal tissue destruction brought on by microwave energy absorbed in the ablation zone.

• Merge Healthcare (Milwaukee) reported the release of FusionWeb, a zero-client software platform that enables secure Web access for the real-time exchange of patient information, procedure reports and digital images. The first FusionWeb application developed specifically for referring clinicians gives radiology providers of any size a cost-effective means of improving system interoperability and workflow efficiency, and delivers on the common desire for an image enabled electronic health record (EHR). the FusionWeb application is available for any diagnostic imaging practice. The browser-based workspace allows imaging centers and hospitals to brand and maintain their portal for optimal use and efficiency. Merge claims that when bundled with Fusion RIS and PACS products, the FusionWeb application provides online order entry and visibility into patient status for referring physicians.

• Sysmex (Mundelein, Illinois) said that its Sysmex XE-2100D Automated Hematology Analyzer has been cleared by the FDA for blood processing center Quality Control release testing of post-processed red blood cell and platelet components collected using a variety of anticoagulants. Historically, the Sysmex XE-2100D had been cleared for in vitro diagnostic use in clinical laboratories and donor centers as a multi-parameter hematology analyzer for whole blood samples using EDTA anticoagulant .

• VisEn Medical (Bedford, Massachusetts) reported the launch and availability of a new Fluorescence Molecular Tomography (FMT) imaging system the FMT 1500, and an advanced version of its FMT 2500, the FMT 2500 LX. The FMT 2500 LX offers more imaging channels, greater functionality, increased imaging speeds and a broader range of application areas than previously available. Both the FMT 1500 and FMT 2500 LX are based on VisEn's FMT Quantitative Tomographic Imaging platform and both enable unparalleled true quantification of in vivo biomarkers for measuring disease progression and therapeutic efficacy in research and drug development.

• W. L. Gore & Associates (Flagstaff, Arizona) said that several physicians recently presented interim data from ongoing GORE PROPATEN Vascular Graft studies to clinical audiences at the 2009 annual vascular meeting hosted by the Society for Vascular Surgery in June in Denver. One physician reported primary patency rates as high as 100% for below-knee bypasses, Gore said. According to the company, the study updates presented at the meeting support the use of its Propaten Vascular Graft as the prosthetic device of choice in lower limb and dialysis access applications. Gore says its Propaten Vascular Graft is the only vascular graft of its kind on the market approved for hemodialysis access and the treatment of peripheral artery disease. The graft is designed to address the gap in clinical performance between prosthetic and autologous vein grafts by providing a bound heparin technology on the luminal surface that retains its thromboresistant bioactive properties over time. Gore also reported a manufacturing change to its Viabahn endoprosthesis. The company said the change is a result of precision laser trimming technology, which enables the removal of excess material at the device margin, resulting in a contoured edge.